Parkinson’s disease patients with inadequately controlled tremors are being sought for a Phase 2 clinical trial of suvecaltamide, an oral treatment candidate from Jazz Pharmaceuticals. The Phase 2 trial (NCT05642442), which enrolled its first participant late last year, seeks about 160 adults, ages 40-80, with Parkinson’s who have…
Enrollment is still underway in a Phase 2 clinical trial testing Sage Therapeutics’ oral therapy SAGE-718 in people with mild cognitive impairment (MCI) due to Parkinson’s disease. The trial is recruiting Parkinson’s patients at 16 sites across the U.S. Dubbed PRECEDENT (NCT05318937), it’s designed to investigate SAGE-718’s…
Ryne Biotechnology has been awarded $4 million to advance RNDP-001, its investigational dopamine-producing, or dopaminergic, neuron replacement therapy for Parkinson’s disease. The funding comes in the form of a Clinical Stage Research Program grant from the California Institute for Regenerative Medicine (CIRM). Ryne plans to use the award…
A Phase 3 clinical trial of Annovis Bio‘s investigational oral treatment buntanetap in people with early-stage Parkinson’s disease now will open to patients in Europe. This expansion will add 48 new trial sites in Italy, Spain, Hungary, Poland and Germany, joining about 50 sites actively recruiting in the U.S.
A small group of people with Parkinson’s disease adhered well to an experimental music-based digital therapy to treat gait problems, and reported quality of life gains, meeting the main goals of a small feasibility trial, according to its developer MedRhythms. Preliminary evidence of the trial (NCT04891107) that…
The American Parkinson Disease Association (APDA) will host a free, two-day virtual conference for people with Parkinson’s disease and their caregivers on February 15–16. The program is scheduled to run from 12 p.m. to 3:30 p.m. EST each day. “The APDA Virtual Parkinson’s Conference will include an…
High-frequency stimulation of both the brain’s primary motor cortex (M1) and its dorsolateral prefrontal cortex (DLPFC) — two regions with altered activity in Parkinson’s disease — may be the optimal use of transcranial magnetic stimulation (TMS) in easing Parkinson’s motor symptoms, a meta-analysis study reported. In analyzing data from…
Researchers have developed a video-based algorithm to predict the severity of tremor in Parkinson’s disease patients based on the criteria of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). The new algorithm was found to identify tremors, both resting and postural, with high accuracy — ranging from…
Annovis Bio anticipates an interim data analysis from a Phase 3 trial of its therapeutic candidate buntanetap in people with early-stage Parkinson’s disease will be possible by mid-year, based on current trial enrollment. By then, there will likely be enough patients who’ll have received at least two months…
People with REM sleep behavior disorder (RBD) — an early nonmotor symptom of Parkinson’s disease — were significantly more likely than others to wrongly think their sense of smell was normal when olfactory deficits were evident, a small study found. Parkinson’s patients with RBD also had a diminished sense…
Get regular updates to your inbox.